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Abstract 
Ectosomes (Ects) are a subpopulation of extracellular vesicles formed by the process of plasma membrane 
shedding. In the present study, we profiled ectosome-specific microRNAs (miRNAs) in patients with type 
2 diabetes mellitus (T2DM) and analyzed their pro- and anti-angiogenic potential.  
Methods: We used different approaches for detecting and enumerating Ects, including atomic force 
microscopy, cryogenic transmission electron microscopy, and nanoparticle tracking analysis. 
Furthermore, we used bioinformatics tools to analyze functional data obtained from specific miRNA 
enrichment signatures during angiogenesis and vasculature development.  
Results: Levels of miR-193b-3p, miR-199a-3p, miR-20a-3p, miR-26b-5p, miR-30b-5p, miR-30c-5p, 
miR-374a-5p, miR-409-3p, and miR-95-3p were significantly different between Ects obtained from 
patients with T2DM and those obtained from healthy controls.  
Conclusion: Our results showed differences in the abundance of pro- and anti-angiogenic miRNAs in 
Ects of patients with T2DM, and are suggestive of mechanisms underlying the development of vascular 
complications due to impaired angiogenesis in such patients. 
Key words: angiogenesis, diabetes, extracellular vesicles, microRNA, systems biology 
Introduction 
According to a global report on diabetes by the 
World Health Organization (2016), the global 
prevalence of diabetes mellitus (DM) has exceeded 
400 million patients. Prevalence of DM is highest in 
the Southeast Asia and Western Pacific regions, with 
age-standardized mortality rates of 129.1 and 67.8 
deaths per 100,000 people, respectively [1]. In these 
regions, the majority of patients with diabetes have 
type 2 diabetes mellitus (T2DM). Despite substantial 
progress in the diagnosis and medical care of patients 
with diabetes, the life expectancy of these patients is 
significantly shorter than that of the general 
population [2] Diabetes imposes a large financial 
burden on the global health-care system and human 
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capital. Vascular complications are the major cause of 
increased mortality and morbidity associated with 
DM. Functions of the cardiovascular system, 
including angiogenesis and disease states such as 
atherosclerosis, are seriously altered in hyperglycemic 
conditions, which is typically observed in patients 
with poorly controlled DM. Cardiovascular 
alterations often manifest as macroangiopathies, like 
coronary artery disease (CAD) and stroke, or as 
microangiopathies, like non-healing foot ulcers, 
retinopathy and diabetic nephropathy. 
Of the different circulating extracellular vesicles 
(EVs), submicron-sized ectosomes (Ects) have not 
attracted as much interest as nano-sized exosomes 
have [3, 4]. However, after a study by Wolf (1967) 
describing the origin of Ect-like particles from 
platelets, numerous studies have investigated the 
possible mechanisms underlying Ect formation [5]. 
Ects belong to a large family of membrane vesicles or 
EVs, also referred to as microparticles (MPs), that are 
released in an evolutionarily-conserved manner in 
both prokaryotes and eukaryotes [6].  
Ects retain many features of their parental cells, 
including specific surface antigens and receptors [7]. 
Therefore, characteristics of Ects are based on their 
size and their specific molecular signature, with some 
surface proteins and phosphatidylserine (PS) being 
the key identifiers of Ects [6]. PS-positive Ects can be 
easily distinguished from other circulating EVs 
through annexin V or lactadherin binding [8, 9]. 
In the blood, platelets and endothelial cells are 
the main source of circulating Ects; however, under 
stress conditions such as hypoxia, inflammation, and 
diabetes, other blood cells, including macrophages 
and neutrophils, release several EVs [10, 11]. 
Endothelial cell- and platelet-derived Ects substan-
tially affect the cardiovascular system, especially 
endothelial cells and hemostasis [12-14]. Numerous 
studies suggest that endothelial cell-derived Ects exert 
an anti-vasorelaxing effect on other endothelial cells, 
promote hemostasis, and exert procoagulant effects 
[12, 15]. In contrast, platelet-derived Ects increase the 
adhesion of hematopoietic stem/progenitor cells to 
the endothelium, significantly improving their 
engraftment [16], and regulate cell migration and 
neovascularization [17, 18]. 
Changes in EV levels and heterogeneity have 
been observed in the circulating blood of patients 
with type 1 diabetes mellitus (T1DM) and T2DM. 
Although patients with T1DM and T2DM show an 
increase in overall Ect levels, patients with T1DM 
have a higher number of platelet-derived Ects than 
patients with T2DM. Moreover, the procoagulant 
activity of Ects is correlated with the levels of glycated 
hemoglobin (HbA1C) in patients with T1DM [19]. In 
contrast, the procoagulant activity of Ects is lower in 
patients with T2DM having diabetic retinopathy than 
in those having CAD and diabetic foot syndrome [20]. 
Pioneering studies on EVs performed over a 
decade ago indicate that both exosomes and Ects 
contain RNA, including microRNAs (miRNAs); this 
finding has substantially renewed interest in EVs as 
mediators of cell-to-cell communication [21]. miRNAs 
regulate the transcription and translation of several 
genes involved in cell metabolism and various 
canonical and non-canonical pathways in all living 
cells [22]. In DM, modulation of miRNA expression is 
suggested to affect the production of insulin and 
occurrence of diabetic complications [23]. 
Accumulating evidence indicates that most 
circulating miRNAs are carried by AGO protein 
complexes or plasma proteins (lipoproteins) [24, 25]. 
EVs are suggested to function as alternative carriers 
that protect extracellular RNA from RNase 
degradation, indicating that they are efficient tools for 
transport in the human body [26, 27].  
The present study examined miRNAs isolated 
from the plasma of patients with T2DM. In addition, 
this study determined miRNA signatures in 
Ect-enriched and Ect-depleted plasma fractions and 
analyzed the pro- and anti-angiogenic potential of 
these miRNAs by using bioinformatics and system 
biology tools. 
Methods 
Patients and sample collection 
This study involved 15 patients with T2DM and 
15 control subjects, both groups comprising male and 
female subjects aged between 68 and 82 years (mean 
age, 67.9 ± 5.23 years). Clinical characteristics of the 
study subjects are listed in Table 1. Inclusion criteria 
for diabetic patients and control subjects were similar 
to those described previously [28]. Diabetes was 
defined according to Polish Diabetes Society 
guidelines, based on oral glucose tolerance test 
(OGTT). All T2DM patients were undergoing diabetes 
treatment. Obesity and insulin resistance were not 
criteria for exclusion. Both patients and controls with 
acute coronary syndrome (ACS), acute ischemic 
stroke (IS) or critical limb ischemia were excluded 
from this study if they occurred within 6 months prior 
to the study enrollment. Other criteria for exclusion 
were patients with a history of cancer, renal and liver 
failure, and past or present systemic inflammation as 
defined by high-sensitivity C-reactive protein 
(hs-CRP) levels above 10 mg/L. 
Blood samples from all the subjects were 
obtained at the same time of the day (between 08:00 
and 10:00 A.M.) under fasting conditions by 
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performing venipuncture of the antecubital vein with 
a >21 gauge needle and by applying a light 
tourniquet. Approximately 2–3 mL blood was initially 
withdrawn but not included in the analysis. Blood for 
miRNA profiling was collected and mixed with an 
anticoagulant, sodium citrate, centrifuged twice at 
2500 × g for 15 min to obtain platelet-poor plasma 
(PPP). The blood samples were subsequently treated 
with an anticoagulant, EDTA, for performing 
hematological analysis and determining HbA1C 
levels. Biochemical and biomarker analyses were 
performed by collecting the blood samples in serum 
separator tubes. Plasma and serum samples were 
aliquoted, and frozen at –80 °C for further analyses. A 
schematic description of the procedure is presented in 
Figure 1. 
 
Table 1. Characteristics of study groups  
Variable Type 2 diabetes 
(n=15) 
Control group 
(n=15) 
p 
Gender: Female/Male (N) 1/14 0/15 NS 
Age (years) 67 (65-71) 65 (63-71) 0.337 
BMI (kg/m2) 30.25 ± 3.76 25.23 ± 1.22 <0.0001 
Current smokers (N/%) 1/6.7 0/0 0.34 
Former smokers (N/%) 4/26.7 3/20 0.73 
Alcohol consumption (N/%) 3/20 5/33.3 0.53 
Duration of diabetes (years) 6 (3-12) NA - 
Hypertension (N/%) 8/53.3 0/0 0.01 
Other cardiac diseases (N/%) 1/6.7 0/0 0.34 
Peripheral atherosclerosis 
(N/%) 
2/13.3 1/6.7 0.58 
Retinopathy (N/%) 1/6.7 0/0 0.34 
Glucose (mM)  8.96 ± 3.17 6.11 ± 0.97 0.003 
HbA1C (%) 7.5 (7.1-7.8) NA - 
hs-CRP (mg/L) 0.81 ± 0.67 0.64 ±0.87 0.56 
TC (mM) 4.11 ± 0.87 4.89 ± 0.55 0.007 
CHOL LDL (mM) 1.94 ± 0.64 2.95 ± 0.45 <0.0001 
CHOL HDL (mM) 1.13 (1.05-1.26) 1.23 (1.15-1.27) 0.169 
TG (mM) 2.17 (1.40-2.59) 1.36 (1.09-1.73) 0.022 
Medications 
Aspirin (N/%) 5/33.3 2/13.3 0.31 
Insulin (N/%) 5/33.3 NA - 
Metformin (N/%) 9/60 NA - 
Sulphonylourea (N/%) 6/40 NA - 
Hypotensive treatment (N/%) 9/60 NA - 
Statins (N/%) 5/33.3 1/6.66 0.13 
Fenofibrates (N/%) 1/6.7 0/0 0.34 
BMI: body-mass index; CHOL HDL: cholesterol high-density lipoprotein fraction; 
CHOL LDL: cholesterol low-density lipoprotein fraction; HbA1C: glycated 
haemoglobin A1C fraction; hs-CRP: high sensitivity C-reactive protein; TC: total 
cholesterol; TG: triglycerides. 
Values are given as a mean ± standard deviation (SD), a median with an 
interquartile interval (Q1-Q3) or the number and percentage (%). Bold means 
statistically significant difference between the two groups at p<0.05 
 
Ethics committee approval and patient 
consent 
The study complied with the Declaration of 
Helsinki, and the study protocol was approved by the 
Jagiellonian University Bioethics Committee 
(permission no. KBET/206/B/2013, extended until 
December 31, 2017) [28]. Informed consent was 
obtained from all the study subjects. 
Determination of biochemical parameters 
Biochemical parameters, including triglyceride, 
LDL-C, and HDL-C levels, were determined using 
MaxMat analyzer with ELITech Clinical Systems tests 
(Puteaux, France), with a limit of detection (LoD) of 
0.06 mM. hs-CRP was determined using APTEC 
Ultra-Sensitive CRP test (APTEC Diagnostics NV, 
Belgium), with a LoD of 0.13 mg/L. HbA1C level was 
measured by performing HPLC with D-10 
Hemoglobin Testing System (Bio-Rad Laboratories, 
Inc., Hercules, California, USA), certified by the 
National Glycohemoglobin Standardization Program 
(NGSP) organization. 
Ect preparation from plasma samples 
PPP was thawed in a water bath at 37 °C to 
prevent cryoprecipitation, mixed, and centrifuged at 
16,000 × g and 4 °C for 90 min to obtain Ect-enriched 
and Ect-depleted plasma fractions, according to 
Zheng et al., with some modifications including long 
16,000 × g centrifugation [29]. The Ect-enriched 
plasma fraction was frozen at −80 °C for performing 
subsequent analyses (Figure 1). 
Extracellular vesicle (Ect) detection 
Atomic force microscopy  
Atomic force microscopy (AFM) images of the 
Ect-enriched and Ect-depleted plasma fractions were 
obtained using NanoWizard (JPK Instruments AG, 
Berlin, Germany). All experiments were performed in 
distilled water using a commercial liquid cell (JPK 
Instruments, Berlin). V-shape gold-coated cantilevers 
(MLCT cantilever; Bruker Nano Inc., Billerica, MA, 
USA) with nominal spring constants of 0.01 N/m 
were used for scanning in fluid. Surface images (256 × 
256 pixels) were obtained from a scan size of 10 × 10 
μm and a scan rate of 0.4 Hz. Approximately 10–15 
images of the surface were obtained for each sample. 
The size, cross-section, height, and diameter of all the 
EVs, including Ects, were calculated using JPK 
software (JPK Instruments). 
Cryogenic transmission electron microscopy  
Cryogenic transmission electron microscopy 
(Cryo-TEM) of the Ect-enriched plasma fraction was 
performed using a Tecnai F20 TWIN microscope (FEI 
Company, USA) equipped with a field emission gun 
and operated at an acceleration voltage of 200 kV. 
Micrographs were recorded using an Eagle 4k HS 
camera (FEI Company) and processed using TIA 
software (FEI Company). Specimens were prepared 
by vitrifying a particle aqueous solution on grids with 
a holey carbon film (Quantifoil R 2/2; Quantifoil 
Micro Tools GmbH, Jena, Germany). The grids were 
activated for 15 s in oxygen/argon plasma by using 
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Fischione 1020 plasma cleaner (E.A. Fischione 
Instruments, Inc., Export, PA, USA). Samples were 
prepared by applying a droplet (2 µL) of the solution 
onto the grid, blotting with a filter paper for 2 s, and 
immediately freezing in liquid ethane using a 
completely automated blotting device (Vitrobot Mark 
IV; FEI Company, Hillsboro, OR, USA). The vitrified 
specimens were kept in liquid nitrogen until they 
were inserted into a Cryo-TEM holder (Gatan 626; 
Gatan Inc., Pleasanton, CA, USA) and analyzed with a 
TEM at −178 °C. 
Transmission electron microscopy 
The Ect-enriched plasma fraction was washed 
with PBS and centrifuged at 18,000 × g (20 min, 4 °C). 
Supernatant was discarded and pelleted ectosomes 
were fixed with 2.5% glutaraldehyde in 0.1 M 
cacodylic buffer (CB) overnight at 4 °C. Then, samples 
were washed four times for 15 min with 0.1 M CB and 
then postfixed for 1 h in 1% osmium tetroxide/0.1 M 
CB solution. Subsequently, samples were dehydrated 
by passing through a graded ethanol series (50%, 70%, 
80%, 90%, and 100%, 5 min each), embedded in 
PolyBed 812 (epoxy resin) and polymerized for 48 h at 
60 °C. Ultrathin sections were prepared with an EM 
UC7 Leica ultramicrotome and collected on a copper 
mesh; the latter was covered with formvar film. 
Finally, the sections were contrasted with the use of 
uranyl acetate and lead citrate, and viewed on a JEOL 
JEM 2100HT TEM at 80 kV accelerating voltage. 
 
Figure 1. Circulating Ects and plasma supernatant: workflow for miRNA extraction and analysis. Platelet-poor plasma (PPP) was harvested from blood samples of 
patients by centrifugation. The plasma was aliquoted in Eppendorf tubes (350 mL) and was stored at –80 °C. Ects were separated by centrifugation, and two plasma fractions, 
namely, Ect-enriched and Ect-depleted plasma fractions, were used for further analyses (adapted from [30]). 
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Extracellular vesicle (Ect) enumeration  
Nanoparticle tracking analysis 
The samples were thawed on ice and were 
vortexed immediately before performing nanoparticle 
tracking analysis (NTA). To prevent EV aggregation, 
all the samples were diluted to 100× in HEPES buffer 
(10 mM HEPES/NaOH, 140 mM NaCl, and 2.5 mM 
CaCl2, pH 7.4). NTA was performed using a 
NanoSight NS500 (Malvern Instruments Ltd., 
Malvern, United Kingdom) equipped with a sample 
chamber and a 405 nm laser. The assay was 
performed at room temperature (23.3 °C ± 0.1 °C), and 
particles present in the samples were visualized based 
on light scattered by them when illuminated by the 
laser light. Data were captured and analyzed using 
NTA 2.3 Build 0025 software (NanoSight NS500, 
Malvern Instruments Ltd., Malvern, United 
Kingdom). All the samples were analyzed for 30 s, 
with manual shutter and gain adjustments in 
advanced settings. Mean squared displacement of 
each particle tracked was measured simultaneously to 
determine the particle diffusion coefficient (Dt), 
sphere-equivalent, and hydrodynamic radius (R) 
using the Stokes–Einstein equation Dt = KbT / 6ηRπ, 
where Kb is Boltzmann’s constant, T is temperature, η 
is solvent viscosity, and R is the hydrodynamic radius 
of the particle. Thus, NTA helped in measuring both 
the size and concentration of EVs. 
Analysis of the procoagulant activity of Ects 
Ect concentration was determined by performing 
Zymuphen MP Activity assay based on the 
procoagulant activity of the human plasma (through 
thrombin generation) by using a manual method (cat. 
no. 521096; Hyphen BioMed SAS, Neuville sur Oise, 
France), and was expressed as MP concentration (in 
nM). The assay was developed in an end-point mode. 
Absorbance was measured at 405 nm, with a reference 
wavelength of 690 nm, by using Infinite F200 Pro plate 
reader (Tecan Group Ltd., Männedorf, Switzerland) at 
3 min after substrate introduction at 37 °C and 
reaction termination. The detection threshold was set 
at <0.05 nM, and intra-assay variability was set at 
<8%. 
miRNA profiling 
miRNA extraction 
miRNAs were extracted from the Ect-enriched 
and Ect-depleted plasma fractions by using miRNeasy 
Serum/Plasma Kit (Qiagen) and Trizol LS Reagent 
(Invitrogen). RNA yield and concentration were 
determined by performing capillary electrophoresis 
with Agilent Bioanalyzer 2100 and Eukaryote Total 
RNA PicoChip (Agilent Technologies, Inc., Santa 
Clara, CA, USA). An average of 144 ± 89 and 42.6 ± 
45.9 pg/µL total RNA was recovered from 50 µL of 
Ect-enriched and Ect-depleted plasma fractions, 
respectively. Electropherograms of miRNAs present 
in Ect-enriched and Ect-depleted plasma fractions are 
presented in Figure 2.  
miRNA analysis by quantitative PCR 
Extracted miRNA from the Ect-enriched fraction 
and supernatants was reverse transcribed using a 
polyadenylation and cDNA synthesis kit (Exiqon). 
Before cDNA synthesis, RNAs were spiked with a 
synthetic miRNA (UniSp6, Exiqon) that served as a 
control for cDNA synthesis. Screening for 
differentially-expressed miRNAs in ectosomes was 
performed by using a low-density qPCR array, 
Serum/Plasma miRCURY LNA PCR Panel V1 
(Exiqon) (plate layout shown in Table S1) in a Viia7 
real-time PCR system (Thermo Fisher Scientific, 
Waltham, MA, USA) equipped with a 384-well 
reaction plate. qPCR was performed using SYBR 
Green Master Mix Universal RT (Exiqon) under the 
amplification conditions recommended by the 
manufacturer. Amplification data were processed by 
 
 
Figure 2. Fluorescence profiles of isolated miRNAs determined by capillary electrophoresis using Agilent 2100 Bioanalyzer PicoChip. Fluorograms were 
merged together according to a nucleotide size axis. (A) Ect-enriched and (B) Ect-depleted plasma fractions. For comparison, miRNAs were isolated from the same samples by 
using the miRNeasy Serum/Plasma Kit. Blacks arrow indicate marker dye, blue arrows indicate short RNA fragments (miRNAs), and red arrows indicate 18S and 28S rRNAs. 
 Theranostics 2018, Vol. 8, Issue 14 
 
 
http://www.thno.org 
3879 
the ΔCT method with a global normalization approach 
using an open source DataAssist 3.0 software (Thermo 
Fisher Scientific). Fold changes were calculated by the 
∆∆CT method, and statistically significant variations 
among different groups were determined by 
calculating adjusted p-values using the Benjamini– 
Hochberg false discovery rate procedure. Specific 
candidate miRNAs were chosen from screening 
results and individually validated in an additional 
cohort of patients by qPCR using specific LNA 
primers (Exiqon) along with seven additional pro- 
and anti-angiogenic miRNAs from previously 
described studies (Table 2). For individual qPCR 
validation, we performed three technical replicates 
per sample. Amplification data were also processed 
using the ΔCT method using the synthetically spiked 
miRNA as a normalization control. 
Analysis of miRNA targets and functional interactions 
Validated miRNA–target relationships were 
determined using miRNet database [31]. Functional 
interactions between proteins were predicted using 
STRING database by considering a global interaction 
score of >0.9 [32]. A graphical network showing 
significant miRNAs and functionally corresponding 
genes was constructed using NAViGaTOR software 
[33]. 
Statistical analysis 
Statistical analyses were performed using 
Statistica 12.0 package (StatSoft Polska, Kraków, 
Poland). Distribution of variables was examined 
using Kolmogorov–Smirnov normality test. 
Quantitative variables were characterized using 
descriptive statistics, i.e., mean and standard 
deviation (SD) for normally distributed data or 
median and interquartile interval (Q1–Q3) for 
non-normally distributed data. Qualitative variables 
were compared using two-sided Chi-square and 
Fisher’s exact tests. Student's t-test (normally 
distributed data) or Mann–Whitney U test 
(non-normally distributed data) was used to 
determine significant differences between variables. 
Statistical significance was set at p < 0.05. For the 
PCR-array analysis (volcano plots and heat maps), a 
cut-off for level of fold-change of >2 and p-value < 
0.05 were established. Additionally, to reveal the role 
of classical cofounders in diabetes (age, BMI, arterial 
hypertension and diabetes duration) the authors 
applied a logistic regression model in miRNA analysis 
based on the median miRNA expression value (1 for 
higher, 0 for lower values). 
Results 
Characterization of plasma-derived Ects 
AFM and Cryo-TEM detected Ects and smaller 
EVs (exosomes) in the Ect-enriched and Ect-depleted 
plasma fractions (Figure 3 and Figure 4). AFM 
showed the abundance of large vesicles such as Ects 
(mean height, ~200 nm) in the Ect-enriched fraction 
obtained by performing high-speed centrifugation 
(Figure 3). The average height of the identified 
vesicles in the Ect-depleted fraction was lower than 
that in the Ect-enriched fraction (Figure 3C). 
Cryo-TEM detected Ects in the Ect-enriched plasma 
fraction obtained from patients with uncontrolled 
(Figure 4B) and controlled diabetes (Figure 4C). Ects 
were detected as typical multilayered vesicles with a 
dense cargo.  
 
Table 2. Target sequences and nomenclature of selected miRNAs analyzed in the study. Accession sequences and names are presented 
according to miRBase 21. 
miR name (human) microRNA target sequence Sequence reference LNA™ microRNA PCR primer set 
hsa-miR-126-3p UCGUACCGUGAGUAAUAAUGCG MIMAT0000445 EQ-204227 
hsa-miR-126-5p CAUUAUUACUUUUGGUACGCG MIMAT0000444 EQ-206010 
hsa-miR-193b-3p AACUGGCCCUCAAAGUCCCGCU MIMAT0002819 EQ-204226 
hsa-miR-199a-3p ACAGUAGUCUGCACAUUGGUUA MIMAT0000232 EQ-204536 
hsa-miR-20a-3p ACUGCAUUAUGAGCACUUAAAG MIMAT0004493 EQ-204052 
hsa-miR-221-3p AGCUACAUUGUCUGCUGGGUUUC MIMAT0000278 EQ-204532 
hsa-miR-23b-3p AUCACAUUGCCAGGGAUUACC MIMAT0000418 EQ-204790 
hsa-miR-26a-5p UUCAAGUAAUCCAGGAUAGGCU MIMAT0000082 EQ-206023 
hsa-miR-26b-5p UUCAAGUAAUUCAGGAUAGGU MIMAT0000083 EQ-204172 
hsa-miR-29a-5p ACUGAUUUCUUUUGGUGUUCAG MIMAT0004503 EQ-204430 
hsa-miR-30b-5p UGUAAACAUCCUACACUCAGCU MIMAT0000420 EQ-204765 
hsa-miR-30c-5p UGUAAACAUCCUACACUCUCAGC MIMAT0000244 EQ-204783 
hsa-miR-374a-5p UUAUAAUACAACCUGAUAAGUG MIMAT0000727 EQ-204758 
hsa-miR-409-3p GAAUGUUGCUCGGUGAACCCCU MIMAT0001639 EQ-204358 
hsa-miR-495-3p AAACAAACAUGGUGCACUUCUU MIMAT0002817 EQ-206015 
hsa-miR-95-3p UUCAACGGGUAUUUAUUGAGCA MIMAT0000094 EQ-204288 
hsa-let-7i-5p UGAGGUAGUAGUUUGUGCUGUU MIMAT0000415 EQ-204394 
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Figure 3. AFM and analysis of EVs in the Ect-depleted (left) and Ect-enriched (right) plasma fractions from a representative patient with T2DM. Samples 
were immobilized on poly-L-lysine-coated slides. AFM images of EVs. Presence of large vesicles was confirmed in the Ect-enriched (A) and depleted plasma fractions (B). (C-D) 
The mean value of the height of the observed structures calculated based on AFM images. Appropriate size distribution histograms of immobilized EVs in both the plasma 
fractions showing the presence of Ect populations. Diameters are expressed as mean ± standard error. 
 
Figure 4. Characteristics of Ects present in the Ect-enriched and Ect-depleted plasma fractions. Representative wide-field and magnified cryo-TEM images of Ects 
isolated from a control subject (A-B) and a patient with diabetes (glucose level: 12.02 mM; HbA1C level: 9.2%) (E-F). Representative plots of NTA size distribution of EVs in 
Ect-enriched and Ect-depleted plasma fractions from the control group (C-D) and diabetic patients (G-H). Samples were analyzed in 1000 × dilutions. 
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Figure 5. Enumeration and characteristics of Ects present in the Ect-enriched and Ect-depleted plasma fractions. (A) Number of microvesicles present in the 
Ect-enriched and Ect-depleted plasma fractions obtained from diabetic patients (DM) compared with that in the Ect-enriched and Ect-depleted plasma fractions obtained from 
healthy controls (Control), as determined by performing nanoparticle tracking analysis (NTA). (B) Ects particle size as determined by NTA in both groups of samples. (C) PS 
(phosphatidylserine) procoagulant activity exposed on EVs as quantified by Zymuphen MP assay. Whisker plots in (A) and (C) represent data as median (box) with interquartile 
interval (10-90) showing the outliers. Depicted p-values in (A) and (C) between the studied groups of patients were calculated by a two-tailed non-parametric Mann-Whitney test. 
 
NTA analysis did not show significant 
differences in EV density (concentration) between 
T2DM and controls in the Ect-enriched fraction: 36.5 
(19.7-63.7) 106/µL vs. 45.2 (29.5-59.8) 106/µL (p = 0.8); 
or in the Ect-depleted fraction: 33.7 (10.3-43.3) 106/µL 
vs. 42.7 (14.2-20.8) 106/µL (p = 0.2) (Figure 5A). 
Similarly, differences in EVs were detected: 148 
(144-152) nm vs. 137 (130-191) nm (p = 0.6); and 152 
(143-160) nm vs. 165 (100-183) nm (p = 0.9) (Figure 
5B). Significant difference in PS-exposed (procoagu-
lant) concentrations between T2DM and controls were 
observed in the Ect-enriched fraction: 19.10 
(18.34-20.59) nM vs. 13.15 (10.31-17.01) nM (p = 
0.0001); as well as in the Ect-depleted fraction: 4.21 
(2.05-6.81) nM vs. 1.68 (0.48-3.72) nM (p = 0.01) 
(Figure 5C). 
Ectosomes from patients with T2DM showed a 
specific miRNA enrichment signature 
miRNA content in Ects obtained from patients 
with T2DM and healthy controls was determined by 
performing low-density qPCR array with LNA 
primers against 179 circulating miRNAs (Table S1). 
miRNA levels were compared with those in 
corresponding paired supernatants obtained during 
Ect purification by using the same approach (Figure 
6). We identified 25 Ect-specific miRNAs in samples 
obtained from healthy controls and 28 Ect-specific 
miRNAs in samples obtained from patients with 
T2DM. Of the 28 miRNAs identified in samples 
obtained from patients with T2DM, 10 miRNAs, 
namely, hsa-miR-20a-3p, hsa-miR-26a-5p, hsa-miR- 
26b-5p, hsa-miR-29a-5p, hsa-miR-374a-5p, hsa-miR- 
30b-5p, hsa-miR-30c-5p, hsa-let-7i-5p, hsa-miR-199a- 
3p, and hsa-miR-221-3p, were exclusively present in 
Ects isolated from patients with T2DM (Figure 7A). 
To determine the possible functional role of 
miRNAs present in Ects obtained from patients with 
T2DM, we performed a validated target analysis 
followed by graphical network integration, including 
protein–protein interactions (Figure 7B). Our results 
showed that the examined miRNAs targeted genes 
involved in angiogenesis and vasculature 
development. Moreover, the examined miRNAs 
exerted a cooperative regulatory effect on several 
angiogenesis-related mRNA transcripts that were 
simultaneously targeted by two or more of the 
Ect-specific miRNAs. Four Ect-specific miRNAs, 
namely, hsa-miR-26a-5p, hsa-miR-26b-5p, hsa-miR- 
30b-5p, and hsa-miR-30c-5p, simultaneously targeted 
the mRNA transcripts of two genes involved in 
angiogenesis, namely, MTDH and PDCD10, in 
patients with T2DM. Interestingly, pro-angiogenic 
hsa-miR-30 family miRNAs and anti-angiogenic 
hsa-miR-26 family miRNAs simultaneously targeted 
MTDH and PDCD10 mRNA transcripts. Three 
Ect-specific miRNAs targeted seven mRNA 
transcripts in patients with DM. Of these seven 
mRNA transcripts, DDAH and GNA13 mRNA 
transcripts were regulated by pro-angiogenic 
miRNAs and PRX, CYR61, NUS1, PTEN, and WNT5A 
mRNA transcripts were regulated by anti-angiogenic 
miRNAs. Determination of Ect-specific miRNA 
signatures in patients with T2DM identified several 
previously characterized pro- and anti-angiogenic 
miRNAs involved in diverse physiological processes 
(Table 3). 
Validation of Ect miRNA levels in patients with 
DM 
We used two different approaches to validate 
Ect-specific miRNAs. The first approach involved a 
literature search to identify miRNAs involved in the 
pathogenesis of diabetes and its cardiovascular 
complications [23, 27, 34, 35], and the second 
approach involved analysis of qPCR data. 
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Figure 6. qPCR screening of enriched and depleted miRNAs present in Ects compared with those present in corresponding supernatants. Volcano plots of specific miRNAs 
present in the Ect-enriched plasma fraction compared with those present in corresponding supernatants obtained from (A) healthy controls and (B) patients with T2DM. Green 
and red dots represent significantly down- and upregulated miRNAs, respectively, taking into account the following thresholds: p-value < 0.05 and fold-change >2. Heatmap for 
the differentially enriched miRNAs in Ects obtained from (C) healthy control and (D) patients with T2DM. 
 
Table 3. Functional data of Ect-specific miRNAs involved in angiogenesis and vasculature development in patients with T2DM. 
miRNAs Function Comments References 
hsa-miR-20a-3p  Nonrelated The miRNA hsa-miR-20a-5p generated from the same pre-miRNA loop is anti-angiogenic 
 
[67] 
hsa-miR-26a-5p Anti-antiogenic miR-26a targets a SMAD1-Id1-p21WAF/CIP1/p27 signaling axis and inhibits angiogenesis in endothelial cells. In contrast, 
pro-angiogenic stimuli such as VEGF or TNF-a reduced miR-26a expression in endothelial cells. 
 
[68] 
hsa-miR-26b-5p Anti-antiogenic Both in vitro and in vivo studies showed that miR-26b-5p could suppress vascular mimicry and angiogenesis by 
down-regulating the expression of VE-cadherin, Snail and MMP2 and could inhibit the apoptosis of hepatocellular 
carcinoma cells 
 
[69] 
hsa-miR-29a-5p  Nonrelated The miRNA hsa-miR-29a-3p generated from the same pre-miRNA loop is anti-angiogenic [70] 
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miRNAs Function Comments References 
 
hsa-miR-374a-5p  Nonrelated The isomer miRNA hsa-miR-374b is anti-angiogenic 
 
[71] 
hsa-miR-30b-5p  
hsa-miR-30c-5p 
Pro-angiogenic 
 
Overexpression of hsa-miR-30 family in endothelial cells led to increased vessel number and length in an in vitro model of 
sprouting angiogenesis 
 
[72] 
hsa-let-7i-5p Hypertension Let-7 family targets the FGF5 transcript in microvascular endothelial cells 
 
[73] 
hsa-miR-199a-3p Pro-angiogenic MiR-199a-5p, promotes metastatic invasion, angiogenesis, and colonization in melanoma by targetting ApoE and the 
heat-shock factor DNAJA4. 
 
[74] 
hsa-miR-221-3p Anti-angiogenic Levels of miR-221/222 were significantly higher in coronary artery disease (CAD). MiR-221-c-kit pathway may play an 
important role in diabetes-associated vascular dysfunction 
[75, 76] 
 
 
 
Figure 7. Functional characterization of Ect-enriched miRNAs in patients with T2DM. (A) Venn diagram representation of Ect-enriched miRNAs compared with 
those present in corresponding supernatants obtained from patients with T2DM and healthy controls. Patients with T2DM showed a specific miRNA enrichment pattern, which 
included 10 unique miRNAs not detected in healthy controls. (B) Integrative analysis of validated targets involved in vasculature development and angiogenesis for the 10 unique 
miRNAs enriched in Ect from T2DM patients. miRNAs are represented as filled triangles, and validated target genes are represented as circles, with a size proportional to the 
number of miRNAs regulating a particular mRNA. miRNA–target gene relationships obtained from the miRNet database [31] are indicated using grey lines. Black lines indicate 
functional interactions between proteins, as determined using the STRING database [32] by using a global interaction score of >0.9. The graphical network representation was 
constructed using the NAViGaTOR software [33]. 
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Figure 8. Levels of the selected Ect-specific miRNAs in 11 patients with T2DM and 11 healthy controls, as determined by performing qPCR with specific 
LNA primers. (A) Pro- and anti-angiogenic miRNAs selected by performing literature mining. (B) miRNAs exclusively enriched in Ects obtained from patients with T2DM and 
selected by performing qPCR screening. Depicted p-values between the studied groups of patients were calculated by a two-tailed non-parametric Mann-Whitney test. 
 
We performed qPCR to validate the levels 
selected by miRNA screening in the Ect-enriched 
plasma fractions obtained from 11 healthy controls 
and 11 patients with DM. Results of qPCR-based 
validation are shown in Figure 8. Of the reference 
miRNAs identified by performing a literature search, 
hsa-miR-193b-3p and hsa-miR-95-3p were signifi-
cantly enriched in the Ect-enriched plasma fraction 
obtained from patients with T2DM (p = 0.015 and p = 
0.041, respectively; Figure 8A). Interestingly, 
hsa-miR-409-3p was significantly downregulated in 
the Ect-enriched plasma fraction obtained from 
patients with T2DM (p = 0.004). Of the Ect-enriched 
miRNAs selected by performing miRNA screening, 
levels of five among them were significantly 
increased, namely, has-let-7i-5p (p = 0.006), 
hsa-miR-199a-3-5p (p = 0.001), hsa-miR-26b-5p (p = 
0.012), hsa-miR-30b-5p (p = 0.01) and hsa-miR- 
374a-5p (p = 0.0001). Another three of the selected 
miRNAs had a tendency to increase: has-miR-20a-3p 
(p = 0.064), has-miR-26a-5p (p = 0.075) and 
hsa-miR-30c-5p (p = 0.055) in the Ect-enriched plasma 
fraction obtained from patients with T2DM (Figure 
8B). 
The role of confounding factors on miRNA 
levels in the Ect-enriched fraction 
Age and hypertension are the most confounding 
factors in D2TM. To reveal the role of confounding 
factors in diabetes incidence, the logistic regression 
model was applied. We found that none of the 
classical risk factors interfered significantly with 
analyzed miRNA levels in diabetic patients (Table 
S2). 
Discussion 
In the present study, we characterized the 
differences in miRNA cargo between Ects isolated 
from T2DM patients and healthy controls by various 
methods. To show their molecular profile and 
physical properties, technical and experimental 
requirements were used to attribute their miRNA 
 Theranostics 2018, Vol. 8, Issue 14 
 
 
http://www.thno.org 
3885 
cargo [3]. The novelty of the present study is the use of 
the array approach to quantify and discriminate 
Ects-enriched miRNAs in diabetic patients.  
Origin and characteristics of circulating Ects in 
T2DM 
Most Ects, especially those released by platelets 
and endothelial cells, are spherical in nature. Ects are 
not formed through exocytosis but are formed by 
outward membrane budding due to the loss of 
calcium-dependent membrane phospholipid 
asymmetry, cytoskeletal rearrangement, and cell 
surface shedding [36]. Cryo-TEM allowed us to detect 
very small structures ranging from ~5 to 200–300 nm 
in size, even in aqueous samples in a virtually 
artifact-free manner. In the present study, plasma 
samples were placed on a grid, and the small liquid 
film was rapidly frozen to 90 K to prevent the 
formation of ice crystals and maintain the 
transparency of the frozen water film in an 
amorphous state. We confirmed the multilayered 
structure of large microvesicles (Ects) encapsulating 
small vesicles, which was not abundant in the control 
sample. This finding concurs with previous 
observations by Isseman et al. in their Cryo-TEM 
study [37]. Additionally, we did a TEM imaging 
analysis that allowed us to characterize average EV 
size within a similar range to that in the cryo-TEM 
study. Nevertheless, the direct measurement of 
diameter by means of TEM is unreliable after the 
additional washing steps during sample preparation, 
which has been discussed elsewhere [6]. In the present 
study, we performed additional TEM imaging to 
visualize circulating Ect morphology in the plasma 
(Figure S1).  
In the plasma, platelets are considered as the 
main source of EVs [10]. Cytometric analysis of 
plasma obtained from patients with T2DM showed 
that EVs originate from other cellular sources, of 
which most have been previously characterized as 
being CD36 positive [38]. Both Ects and apoptotic 
bodies are released by T lymphocytes under stress 
conditions, and these vesicles induce vascular 
hyperactivity in response to vasoconstrictors [39]. 
Endothelial cell-derived Ects impair endothelial 
function in vitro by decreasing acetylcholine-induced 
vasorelaxation and nitric oxide production [12]. 
Results of a Matrigel assay performed in a previous 
study showed that endothelial cell-derived Ects affect 
the formation of vascular networks by decreasing 
total capillary length, mesh number, and branching 
points, and increasing mesh area, thus confirming 
their anti-angiogenic role [40]. In contrast, 
platelet-derived Ects strongly activate angiogenesis by 
promoting the proliferation, survival, migration, and 
tube formation by human umbilical vein endothelial 
cells [17]. Increasing evidence indicates that EVs 
(mainly exosomes) derived from the platelet-rich 
plasma promote the re-epithelization of chronic 
cutaneous wounds by effectively inducing 
proliferation and migration of endothelial cells and 
fibroblasts in a diabetic rat model [41].  
We can conclude that differences in Ects 
characteristics and biological effects result from not 
only their different origins but also their pathology.  
Specific miRNA signature in circulating Ects 
The choice of the high-speed centrifugation 
technique for EV purification facilitates the separation 
of two fractions of PPP: Ect-enriched and Ect-depleted 
fractions. This is a method of choice used previously 
in a number of studies with different modifications 
[13, 29, 42]. In the Ect-enriched fraction, two types of 
ectosomes are usually abundant: those of platelet 
origin, and those of endothelial origin. 
Platelet-derived Ects deliver various extracellular 
miRNAs to different vascular cells [27]. Activated 
platelets and platelet-derived microvesicles contain 
miRNAs and other non-coding RNAs [43]. Of these 
RNAs, two miRNAs, namely, hsa-miR-223-3p and 
hsa-miR-126-3p, are interesting because of their 
biological role and proven abundance in platelets 
[44-46]. miR-223-3p is highly expressed in platelets 
and megakaryocytes. Expression of hsa-miR-223-3p is 
strongly correlated with platelet response to 
antiplatelet therapy, and high miR-223 levels predict 
efficacious platelet inhibition with clopidogrel [44, 
47]. In the present study, qPCR screening did not 
detect significant abundance of hsa-miR-223-3p in the 
Ect-enriched plasma fraction, and in patients with 
T2DM or healthy controls. However, some studies 
have shown that platelet-derived microvesicles 
deliver miR-223 as an effector complex along with 
miRNA machinery protein AGO2 and affect the 
expression of FBXW7 and EFNA1 mRNA transcripts 
[46]. In our previous studies, we have confirmed the 
presence of AGO proteins in larger platelet vesicles 
corresponding to Ects, obtained from activated 
platelets (unpublished data). 
In the present study, mature miRNAs generated 
from the miR-126 precursor locus, i.e., hsa-miR-126-3p 
and hsa-miR-126-5p, were not significantly regulated 
in the Ect-enriched plasma fraction obtained from 
patients with T2DM. Our data differ from those of a 
previous study by Jansen et al., who showed 
decreased expression of circulating hsa-mir-126-3p in 
patients with DM [42]. This discrepancy might be 
because of heterogeneity between the present study 
and the previous study with respect to the inclusion of 
patients with different DM types and absence of 
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information on treatment regimen and duration. In 
contrast, another study showed that circulating 
miR-126 levels are elevated in patients with T2DM 
and are positively correlated with glycemic control 
measure (glucose AUC) [48], which is consistent with 
the present study. miR-126 is expressed in platelets 
and endothelial cells, and circulating miR-126 is 
carried by both platelet- and endothelial cell-derived 
microvesicles. However, results of sorting 
experiments showed that most miR-126 is transferred 
by endothelial cell-derived Ects [27, 49]. These data 
indicate that miR-126 expression can be upregulated 
and downregulated in cardiovascular diseases and 
suggest that both platelet activity and endothelial cell 
dysfunction affect miR-126 availability [45]. Similarly, 
the level of another miRNA (hsa-miR-495-3p), which 
is suggested to be associated with DM complications, 
was not increased in the Ect-enriched plasma fraction 
in the present study. 
Moreover, we observed that hsa-miR-193b-3p 
and hsa-miR-95-3p expression was significantly 
upregulated in the Ect-enriched plasma fraction 
obtained from patients with T2DM. To the best of our 
knowledge, no study has reported the involvement of 
miR-193 or miR-95 in angiogenesis regulation and 
vascular function, to date. Increased expression of 
miR-95 has been observed in cancer cells, and its 
activity is associated with radioresistance (or 
radiosensitivity) of non-small cell lung cancer [50]. 
miR-95 functions as an oncogene by directly targeting 
sorting nexin 1 and other proteins involved in cell 
proliferation [51]. In contrast to hsa-miR-95-3p, which 
stimulates cell proliferation, hsa-miR-193b exerts an 
anti-proliferative effect [52]. Moreover, accumulating 
evidence suggests that miR-193b inhibits the 
migration and invasion of cancer cells [53]. In the 
present study, we found that these two miRNAs were 
highly expressed in Ects obtained from patients with 
T2DM, suggesting that pro- and anti-proliferation 
processes are dysregulated in T2DM and that Ects 
contribute to the regulation of these processes. 
 Interestingly, hsa-miR-409-3p expression was 
downregulated in the Ect-enriched plasma fraction 
obtained from patients with T2DM. Previous studies 
indicate that cancer-associated stromal-like cells 
release miR-409 through EVs and promote 
epithelial-to-mesenchymal transition (EMT) both in 
vitro and in vivo [54]. EMT is a transdifferentiation 
process responsible for several clinical complications 
in T2DM. In experimental hyperglycemia, TGF-β 
signaling pathway mediates endothelial-to- 
mesenchymal transition (EndMT), which induces 
endothelial damage and increases mesenchymal 
biomarker expression [55]. The results of the present 
study suggest that hsa-miR-409-3p regulates EndMT 
in T2DM. 
In addition, we compared the distribution of 
circulating miRNAs between Ect-enriched and 
Ect-depleted plasma compartments in healthy 
controls and patients with T2DM. Our results showed 
specific distribution patterns of miRNAs between 
both these compartments in healthy controls and 
patients with T2DM. miRNA enrichment patterns in 
Ects isolated from patients with T2DM compared with 
those present in corresponding supernatants 
indicated the presence of pro- and anti-angiogenic 
miRNAs, which were different from that observed in 
healthy controls. Specific exosomal miRNA transfer in 
the context of angiogenesis has already been 
described in the communication between cardiomyo-
cytes and endothelial cells mediated by miR-320 in rat 
models of DM [56]. 
Our results suggest an imbalance in the 
distribution of miRNAs in patients with T2DM, which 
may be associated with the physiological role of these 
miRNAs. This unique molecular signature may vary 
in different DM types showing different progression 
and associated complications [23, 42, 48], suggesting 
the role of genetics in Ect formation. However, one 
should consider environmental factors and baseline 
characteristics of patients (disease duration, age, 
weight, and gender). Moreover, relative tissue 
specificity, expression, and stability of different 
miRNAs significantly affect miRNA expression. 
Role of Ect-enriched miRNAs in the regulation 
of angiogenesis 
We found that both pro- and anti-angiogenic 
miRNAs were upregulated in Ects and that the 
miRNA expression pattern was associated with 
various angiogenic genes. As proven, Ect-enriched 
miRNAs in patients with T2DM included miRNAs 
that exerted antagonistic effects on angiogenesis and 
vasculature development (Table 3). miR-26 family 
miRNAs and miR-221-3p exert anti-angiogenic 
effects, whereas miR-30 family miRNAs and 
miR-199a-3p exert pro-angiogenic effect. Jansen et al. 
showed that DM is associated with reduced 
endothelial miR-126 and miR-26a expression in 
circulating microvesicles; however, the authors 
analyzed patients with different DM types and for 
varied durations [42]. These two miRNAs exert both 
pro- and anti-angiogenic effects by promoting 
vascular regeneration, inhibiting apoptosis, and 
reducing insulin sensitivity in endothelial cells 
[57-59]. In the present study, we found that 
hsa-miR-26b expression was upregulated in the 
Ect-enriched plasma fraction obtained from patients 
with DM. These results suggest the presence of a 
delicate equilibrium in miRNA cargo that may be 
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associated with the functional regulatory properties of 
Ects in patients with DM. 
Experimental evidence supports this hypothesis 
in other fields. For example, monocyte-derived Ects 
carrying pro-angiogenic miRNAs (miR-150) exert 
strong pro-angiogenic effects, and this pro-angiogenic 
activity of these Ects is attenuated after depletion of 
the pro-angiogenic miRNAs [60]. In stem cells, 
relative proportions of exosomal miRNAs with 
antagonistic regulatory functions are important for 
exerting anti-proliferative effect on cancer cells [61]. 
Moreover, variability of miRNAs in exosomes derived 
from different sarcomas is important for inducing the 
formation of a colonization niche around the primary 
tumor by these miRNAs [62]. 
We previously reported the pro-angiogenic 
potential of Ects with Ects obtained from patients with 
T2DM expressing cytokines and angiogenic factors, 
including those regulated once activated, normal 
T-cell expressed and secreted (RANTES), and 
angiopoietin-2 [30]. Thus, Ects can be considered 
specific miRNA carriers that may promote 
angiogenesis in endothelial cells by targeting different 
angiogenic pathways, including active pSTAT3, 
nuclear factor (NF)-κB, Wnt, PPARγ, and 
ERK5/MAPK7 signaling pathways [23, 63]. 
Moreover, Ect-induced endothelial dysfunction 
should be considered by comparing data from specific 
endothelial biomarkers in T2DM [34]. 
Technical and clinical limitations associated 
with Ect study 
The high diversity of EVs may hamper 
compatible measurement of Ects by using different 
analytical methods. To prevent these complications, 
different biophysical and biochemical properties of 
Ects, including size, mass density, shape, and surface 
antigen expression, can be used for their isolation [64]. 
In the present study, we used high-speed 
centrifugation for performing plasma fractionation 
and Ect fractionation as described elsewhere [29, 30]. 
This strategy cannot fully evade contamination with 
HDL and LDL proteins, which can bind and transfer 
miRNAs within a circulation system [65], as well as 
AGO proteins. To eliminate these effects, we used the 
normalization method to reduce the potential effect 
on miRNA analysis. 
EV number depends on detection techniques 
and different pre-analytical variables such as blood 
collection and handling, plasma preparation, and 
storage conditions. Pre-analytical variables, namely 
collection, handling and storage of samples, have 
been extensively studied in previous work and 
showed insignificant effects over EVs when 
performed in identical conditions [66]. Therefore, 
optimization and standardization of detection 
techniques are important to precisely define 
microvesicles and to prevent false-high or false-low 
quantification. Three ISTH Scientific and 
Standardization Subcommittees (SSC Vascular 
Biology, DIC, and Haemostasis & Malignancy) have 
initiated a project for standardizing the enumeration 
of cellular MPs by performing flow cytometry. Two 
collaborative workshops were implemented to 
establish the resolution and threshold levels of flow 
cytometers currently used in laboratories. Results of 
these workshops showed the potential and laboratory 
limitations of microvesicle evaluation methods [67]. 
Thus, Ect data should be considered in pre-analytical 
and analytical phases as well as with patient 
characteristics, especially for clinical purposes. In the 
present study, we used different imaging methods to 
visualize the presence of EV, such as TEM, cryo-TEM, 
and AFM. The accompanying wide-field images 
(Figure S1) and wide-field cryo-TEM images (Figure 
4A-B, E-F) show potential contaminants, the presence 
of which should be accounted for in data analysis and 
normalization methods. 
The clinical limitation of the present study was 
associated with patient characteristics. Body mass 
index (BMI) was significantly different between 
patients with T2DM and healthy controls. Patients 
with T2DM included in the present study were mostly 
overweight (mean BMI, ~30 kg/m2), which strongly 
increases the risk of T2DM. In our logistic regression 
model, BMI (as well as age and arterial hypertension) 
was analyzed as a potential confounding factor of 
miRNA levels in DM incidence, without any 
significance. However, the effect of gender bias 
should be considered because our study groups were 
not analyzed with due respect to this risk factor. 
Similarly, while smoking behavior was not the subject 
of this study, the role of cigarette smoking on miRNA 
levels cannot be overlooked. 
Subcutaneous adipose tissues, including those 
present in the abdominal area, possess adipose 
mesenchymal stem cells that produce EVs, and these 
cells contribute to the diversity of miRNA profiles in 
Ects [61]. Therefore, excessive fat accumulation should 
be considered as an additional factor that impairs 
angiogenesis in patients with T2DM. Another 
important issue is glucose regulation in patients with 
T2DM and healthy controls. The median HbA1C level 
in patients included in the present study was 7.5% 
(7.1%–7.8%), which was similar to that reported in 
other studies [11, 42], and indicated imbalanced 
glucose regulation in patients with T2DM included in 
the present study. Moreover, two healthy subjects 
included in the present study showed incidentally 
elevated glucose levels, which affected the mean 
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glucose level. However, healthy controls included in 
the present study were not considerably different 
from those included in previous studies. Moreover, 
they were carefully selected with respect to age, 
gender, smoking behavior, and cardiovascular 
diseases (except hypertension). Healthy controls 
differed from T2DM patients with respect to 
biochemical characteristics, having higher total and 
LDL cholesterol levels and lower triglycerides levels 
then T2DM patients, which may affect Ect formation. 
These differences were probably associated with 
hyperlipidemia treatment in patients with DM that 
were included in the present study. Diabetes 
management guidelines recommend the use of statins 
to normalize the lipid profile, and to reduce 
cardiovascular risk in patients with DM; the use of 
antiplatelet and hypotensive drug therapies is also 
recommended [28]. 
Conclusions 
The present study is the first systematic study to 
determine the signatures of Ect-specific miRNAs in 
patients with T2DM, and to analyze their pro- and 
anti-angiogenic potential by using bioinformatics 
tools. Our results clearly show the distribution of pro- 
and anti-angiogenic miRNAs in patients with T2DM, 
as indicated by the upregulation or downregulation of 
miRNAs in the Ect-enriched plasma fraction. This 
finding may highlight a possible mechanism 
underlying the occurrence of vascular complications 
due to impaired angiogenesis in patients with T2DM. 
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